FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Alymsys Patient Brochure False or Misleading: FDA

[ Price : $8.95]

The CDER Office of Prescription Drug Promotion says an Amneal patient brochure for its Avastin biosimilar Alymsys is false or misl...

America First Fee Incentives Discussed in PDUFA Meeting

[ Price : $8.95]

Minutes of the 3/10 and 3/12 PDUFA 8 reauthorization steering committee sessions, progress was reported on the America First fee i...

Granules Steps Up Oversight at Troubled India Facility

[ Price : $8.95]

Granules India Ltd tightens oversight of its manufacturing operations at its largest facility based on FDA-documented compliance i...

Inspection Cites Thermo Fisher Manufacturing Facility

[ Price : $8.95]

FDA cites GMP deficiencies at a facility operated by Thermo Fisher Scientific (Patheon Italia unit) in Ferentino, Italy.

FDA Lifts Partial Clinical Hold on MacroGenics Cancer Study

[ Price : $8.95]

FDA removes partial clinical hold against MacroGenics Phase 2 LINNET study evaluating the investigational cancer therapy lorigerli...

Mass Compounding Threatens FDA Enforcement: Column

[ Price : $8.95]

An FDA Matters column calls on FDA to fully enforce the laws against mass compounding of approved drugs that are not in shortage.

FDA Budget Proposal Signals Push for Tighter Ad Oversight

[ Price : $8.95]

Law firm Sheppard breaks down some of FDAs proposals in its budget documents that industry should keep a close eye on, including n...

Workshop on Novel Surrogate Endpoints for Rare Disease Drugs

[ Price : $8.95]

FDA announces a 5/18 virtual public workshop aimed at advancing the use of novel surrogate endpoints in developing treatments for ...

Insmed Halts Brensocatib Program After Mid-Stage Trial Miss

[ Price : $8.95]

Insmed discontinues development of its drug candidate brensocatib for hidradenitis suppurativa after a mid-stage clinical trial fa...

See Supply Chain Strategy as Core Regulatory Function: Attorney

[ Price : $8.95]

Baker Hostetler attorney Winston Kirton says life sciences companies that are active in both the U.S. and the EU need to change th...